Abstract:Purpose: Colorectal cancer is the second most common cancer in women and the third most common in men worldwide. However, despite current progress, many patients with advanced and metastatic tumors still die from the malignancy. Refractory disease often relies on nicotinamide adenine dinucleotide (NAD)-dependent mechanisms. NAD metabolism and a stable NAD regeneration circuit are required to maintain tissue homeostasis and metabolism. However, high levels of NAD confer therapy resistance to tumors.Experimental Design: Ectopic overexpression of nicotinamide phosphoribosil transferase (NAMPT) and shRNAs in colorectal cancer cell lines, tumorigenic and stemness properties and transcription measurement in culture and in vivo Transcriptional analysis in public databases. Therapeutic approaches.Results: NAMPT, the rate-limiting enzyme responsible for the highest source of physiologic NAD biosynthesis, increases tumorigenic properties and induces cancer stem cell-like properties through pathways that control stem cell signaling, thus enriching the cancer-initiating cell (CIC) population. Furthermore, NAMPT expression correlated with high levels of CIC-like cells in colon tumors directly extracted from patients, and transcription meta-analysis revealed that NAMPT is also a key factor that induces cancer stem pathways in colorectal cancer tumors. This effect is mediated by PARP and SIRT1. In addition, we report a novel NAMPT-driven signature that stratifies prognosis from high to low expression groups. The NAMPT signature contained SIRT1 and PARP1 levels as well as other cancer stem cell-related genes. Finally, NAMPT inhibition increased the sensitivity to apoptosis in both NAMPT-expressing cells and tumorspheres.Conclusions: NAMPT represents a novel therapeutic target in colon cancer progression and relapse, particularly the CIC subset of human colon cancers. Clin Cancer Res; 24(5); 1202-15. ©2017 AACR.

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review

NAMPT: A critical driver and therapeutic target for cancer

Inhibitors of NAD+ Production in Cancer Treatment: State of the Art and Perspectives

Nicotinamide Phosphoribosyltransferase Inhibitors in Cancer Therapy:An Advance

Nicotinamide N-methyltransferase Enhances the Capacity of Tumorigenesis Associated with the Promotion of Cell Cycle Progression in Human Colorectal Cancer Cells.

Data from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery

The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia

Drug Discovery Targeting Nicotinamide Phosphoribosyltransferase (NAMPT): Updated Progress and Perspectives

Nicotinamide Phosphoribosyltransferase (nampt) in Carcinogenesis: New Clinical Opportunities

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death

Nicotinamide phosphoribosyltransferase and its roles in cancer

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery

NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation

Targeting NAD+ Metabolism: Preclinical Insights into Potential Cancer Therapy Strategies

Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship

Regulation of the Nampt-mediated NAD Salvage Pathway and Its Therapeutic Implications in Pancreatic Cancer

Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy

Discovery and Characterization of Novel Small-Molecule Inhibitors Targeting Nicotinamide Phosphoribosyltransferase